EUCTR2011-005882-19-Outside-EU/EEA进行中（未招募）不适用
on-inferiority of GSK Biologicals’ measles-mumps-rubella-varicella (MMRV) vaccine 208136 vs Priorix™ and Priorix™ coadministered with Varilrix™ (comparator) and to evaluate non-inferiority of Priorix™ and MMRV vaccine 208136 vs comparator. - MMRV-053 PRI
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 450
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.
- •Male or female subjects between and including 9 and 10 months of age at the time of the first vaccination.
- •Written informed consent obtained from the the parent or guardian of the subject.
- •Healthy subjects as established by medical history and clinical examination before entering into the study.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 450
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Use of any investigational or non-registered product other than the study vaccines within 30 days preceding the first dose of study vaccine, or planned use during the study period.
- •Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.
- •Planned administration/administration of a vaccine not foreseen by the study protocol starting 30 days prior to administration of any dose of the study vaccine, up to 42 days after the vaccine dose with the exception of hepatitis A vaccine and oral poliovirus vaccine .
- •Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-registered product.
- •Previous vaccination against measles, mumps, rubella and varicella.
- •History of measles, mumps, rubella and/or varicella diseases.
- •Known exposure to measles, mumps, rubella and/or varicella within 30 days prior to the start of the study.
- •Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
- •A family history of congenital or hereditary immunodeficiency.
- •History of allergic disease or reactions likely to be exacerbated by any component of the vaccines including neomycin.
- •Major congenital defects or serious chronic illness.
- •History of any neurologic disorders or seizures.
- •Acute disease at the time of enrolment.
- •Axillary temperature > 37.5°C (99.5°F) / Rectal temperature > 38°C (100.4°F).
- •Administration of immunoglobulins and/or any blood products during the six months before entering the study or planned administration during the study period.
- •Presence of a susceptible high-risk person in the same household during the study period.
研究者
相似试验
已完成
3 期
Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK Biologicals' Meningococcal Vaccine 134612Infections, MeningococcalNCT00465816GlaxoSmithKline611
已完成
3 期
Comparison of GSK Biologicals' Meningococcal Vaccine (GSK134612) and Licensed MenC-CRM197 Vaccine in Healthy ChildrenInfections, MeningococcalNCT00674583GlaxoSmithKline414
进行中（未招募）
2 期
Safety and immunogenicity study of a candidate tuberculosis vaccine in HIV-positive adults.CTRI/2011/091/000065GlaxoSmithKline Biologicals240
已完成
2 期
Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working SeedsRubellaMeaslesVaricellaMumpsNCT00892775GlaxoSmithKline501
进行中（未招募）
不适用
A study to compare the immunogenicity of GSK Biologicals' 10Pn-PD-DiT 4-dose presentation to the licensed 1-dose Synflorix™ (10Pn-PD-DiT) vaccine when co-administered with DTPw-combination vaccine in healthy infants.Infections, PneumococcalEUCTR2014-000750-11-Outside-EU/EEAGlaxoSmithKline Biologicals320